BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.17.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20190310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20191103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200407
DTEND;VALUE=DATE:20200408
DTSTAMP:20200121T225140Z
CREATED:20200121T225140Z
LAST-MODIFIED:20200121T225140Z
UID:7776-1586217600-1586303999@scienceinboston.com
SUMMARY:HMX Pro Genetics - Cancer Genomics and Precision Oncology
DESCRIPTION:HMX Pro online courses are designed to help busy professionals get up to speed on the latest advances in medical science. Each course is taught by Harvard Medical School faculty and include detailed animations and illustrations\, real-life scenarios\, and clinical videos that demonstrate the relevance of what you’re learning – with real patient interactions and cutting-edge treatments. \nBuild your science knowledge and learn what’s behind today’s health care innovations – while having the opportunity to earn a certificate from Harvard Medical School. \nHMX Pro Genetics – Cancer Genomics and Precision Oncology is an advanced course that covers topics including cancer mutations\, tumor sequencing\, cancer therapeutics\, and more. \nThe next course period runs from April 7 – June 19\, 2020. \nApplications are due by March 17. Individual course tuition is $800.
URL:https://scienceinboston.com/event/hmx-pro-genetics-cancer-genomics-and-precision-oncology/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinboston.com/wp-content/uploads/sites/6/2020/01/HMX_TumorSeqGraph_fb.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200407
DTEND;VALUE=DATE:20200408
DTSTAMP:20200121T225140Z
CREATED:20200121T225140Z
LAST-MODIFIED:20200121T225140Z
UID:27437-1586217600-1586303999@scienceinboston.com
SUMMARY:HMX Pro Genetics - Cancer Genomics and Precision Oncology
DESCRIPTION:HMX Pro online courses are designed to help busy professionals get up to speed on the latest advances in medical science. Each course is taught by Harvard Medical School faculty and include detailed animations and illustrations\, real-life scenarios\, and clinical videos that demonstrate the relevance of what you’re learning – with real patient interactions and cutting-edge treatments. \nBuild your science knowledge and learn what’s behind today’s health care innovations – while having the opportunity to earn a certificate from Harvard Medical School. \nHMX Pro Genetics – Cancer Genomics and Precision Oncology is an advanced course that covers topics including cancer mutations\, tumor sequencing\, cancer therapeutics\, and more. \nThe next course period runs from April 7 – June 19\, 2020. \nApplications are due by March 17. Individual course tuition is $800.
URL:https://scienceinboston.com/event/hmx-pro-genetics-cancer-genomics-and-precision-oncology-2/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinboston.com/wp-content/uploads/sites/6/2020/01/HMX_TumorSeqGraph_fb.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200407T080000
DTEND;TZID=America/New_York:20200407T090000
DTSTAMP:20200323T182247Z
CREATED:20200323T182247Z
LAST-MODIFIED:20200323T182247Z
UID:8521-1586246400-1586250000@scienceinboston.com
SUMMARY:Grand Rounds: Disentangling the Links between Emotional Stress and Cardiovascular Disease
DESCRIPTION:Presenter: Ahmed Tawakol\, MD\nCo-Director\, Cardiovascular Imaging Research Center\, Massachusetts General Hospital \nDr Tawakol graduated from Stanford Medical School and did his Medical Residency and Cardiovascular Diseases Fellowship at Brigham and Women’s Hospital. He subsequently completed training in Nuclear Cardiology at Massachusetts General Hospital\, after which he joined the Cardiology Division staff. His clinical focus is in nuclear cardiology and general cardiology\, with a special focus on the identification of patients at highest risk for atherothrombotic event. \nDr Tawakol’s research interest is in imaging of atherosclerosis. His work has focused on developing novel diagnostic approaches and novel treatment strategies for atherosclerosis. To that end\, Dr Tawakol has developed and validated molecular methods to characterize atherosclerotic plaques\, and has made seminal observations validating the use of FDG-PET imaging for the measurement of atherosclerotic plaque inflammation. Currently\, he is leading several multi-center trials to evaluate interventions targeting plaque inflammation and is evaluating the potential clinical role of vascular PET imaging for improving the identification of patients at highest risk for atherothrombotic events. \nEvent Details\nDate/Time: Tuesday\,  April 7 | 8:00am – 9:00am (followed by coffee hour\, 9:00am – 10:00am)\nVenue: Bornstein Family Amphitheater\, Brigham and Women’s Hospital\, 45 Francis St. Boston\, MA\nCost: Free. CME credit available (for in-person and virtual attendance).\nDownload Flier\nSee full schedule \nLive Stream              \n1) If you DO NOT wish to request CME credit for virtual attendance\, view the live stream here.\n2) If you DO want to request CME credit for virtual participation\, to be eligible\, send an email between 8:00-8:30am on Tuesday\, Mar. 3rd with your full name\, degree and organization to jcantlin@bwh.harvard.edu. \nSubmit online questions via Twitter: @HMSOsherCenter (#TawakolApr7)\nTrouble Shooting: If you have trouble with the live stream please email: BWHWebcastTroubleShooting@partners.org
URL:https://scienceinboston.com/event/grand-rounds-disentangling-the-links-between-emotional-stress-and-cardiovascular-disease/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200407T080000
DTEND;TZID=America/New_York:20200407T090000
DTSTAMP:20200323T182247Z
CREATED:20200323T182247Z
LAST-MODIFIED:20200323T182247Z
UID:27442-1586246400-1586250000@scienceinboston.com
SUMMARY:Grand Rounds: Disentangling the Links between Emotional Stress and Cardiovascular Disease
DESCRIPTION:Presenter: Ahmed Tawakol\, MD\nCo-Director\, Cardiovascular Imaging Research Center\, Massachusetts General Hospital \nDr Tawakol graduated from Stanford Medical School and did his Medical Residency and Cardiovascular Diseases Fellowship at Brigham and Women’s Hospital. He subsequently completed training in Nuclear Cardiology at Massachusetts General Hospital\, after which he joined the Cardiology Division staff. His clinical focus is in nuclear cardiology and general cardiology\, with a special focus on the identification of patients at highest risk for atherothrombotic event. \nDr Tawakol’s research interest is in imaging of atherosclerosis. His work has focused on developing novel diagnostic approaches and novel treatment strategies for atherosclerosis. To that end\, Dr Tawakol has developed and validated molecular methods to characterize atherosclerotic plaques\, and has made seminal observations validating the use of FDG-PET imaging for the measurement of atherosclerotic plaque inflammation. Currently\, he is leading several multi-center trials to evaluate interventions targeting plaque inflammation and is evaluating the potential clinical role of vascular PET imaging for improving the identification of patients at highest risk for atherothrombotic events. \nEvent Details\nDate/Time: Tuesday\,  April 7 | 8:00am – 9:00am (followed by coffee hour\, 9:00am – 10:00am)\nVenue: Bornstein Family Amphitheater\, Brigham and Women’s Hospital\, 45 Francis St. Boston\, MA\nCost: Free. CME credit available (for in-person and virtual attendance).\nDownload Flier\nSee full schedule \nLive Stream              \n1) If you DO NOT wish to request CME credit for virtual attendance\, view the live stream here.\n2) If you DO want to request CME credit for virtual participation\, to be eligible\, send an email between 8:00-8:30am on Tuesday\, Mar. 3rd with your full name\, degree and organization to jcantlin@bwh.harvard.edu. \nSubmit online questions via Twitter: @HMSOsherCenter (#TawakolApr7)\nTrouble Shooting: If you have trouble with the live stream please email: BWHWebcastTroubleShooting@partners.org
URL:https://scienceinboston.com/event/grand-rounds-disentangling-the-links-between-emotional-stress-and-cardiovascular-disease-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200414T093000
DTEND;TZID=America/Vancouver:20200417T170000
DTSTAMP:20200413T184213Z
CREATED:20200413T184117Z
LAST-MODIFIED:20200413T184213Z
UID:8660-1586856600-1587142800@scienceinboston.com
SUMMARY:Open Data Science Conference
DESCRIPTION:ODSC East 2020 is one of the largest applied data science conferences in the world. Speakers include core contributors to many open source libraries and languages. Attend ODSC East 2020 and learn the latest AI & data science topics\, tools\, and languages from some of the best and brightest minds in the field.
URL:https://scienceinboston.com/event/open-data-science-conference/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200414T093000
DTEND;TZID=America/Vancouver:20200417T170000
DTSTAMP:20200413T184117Z
CREATED:20200413T184117Z
LAST-MODIFIED:20200413T184117Z
UID:27448-1586856600-1587142800@scienceinboston.com
SUMMARY:Open Data Science Conference
DESCRIPTION:ODSC East 2020 is one of the largest applied data science conferences in the world. Speakers include core contributors to many open source libraries and languages. Attend ODSC East 2020 and learn the latest AI & data science topics\, tools\, and languages from some of the best and brightest minds in the field.
URL:https://scienceinboston.com/event/open-data-science-conference-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200415T090000
DTEND;TZID=America/Vancouver:20200415T100000
DTSTAMP:20200330T174814Z
CREATED:20200330T174402Z
LAST-MODIFIED:20200330T174814Z
UID:8569-1586941200-1586944800@scienceinboston.com
SUMMARY:Webinar: The Modern Mentor
DESCRIPTION:Mentorship has transformative power. In today’s business world\, it has proven to be a critical element of success by getting people in positions of influence actively supporting\, sponsoring and guiding the careers of women as they progress through their careers\, particularly at pivotal decision points. However\, asking someone to mentor you and managing that relationship could be at times nerve-wracking. \nWCT is excited to offer a webinar that will help mentors and mentees achieve the most from any mentorship engagement. Fiona Gao\, a global marketing leader\, and Angela Brown\, President and CEO of Moneris\, recently participated in the WCT Protégé Project. Based on their experience\, they have released a white paper entitled “The Modern Mentor: Reimagining the Interconnectedness of Women in Business\,” which provides excellent advice for those in a mentorship or sponsorship relationship. \nDate: April 15\, 2020\nTime: 9am-10am PST\nRegister: here
URL:https://scienceinboston.com/event/webinar-the-modern-mentor/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200415T090000
DTEND;TZID=America/Vancouver:20200415T100000
DTSTAMP:20200330T174402Z
CREATED:20200330T174402Z
LAST-MODIFIED:20200330T174402Z
UID:27444-1586941200-1586944800@scienceinboston.com
SUMMARY:Webinar: The Modern Mentor
DESCRIPTION:Mentorship has transformative power. In today’s business world\, it has proven to be a critical element of success by getting people in positions of influence actively supporting\, sponsoring and guiding the careers of women as they progress through their careers\, particularly at pivotal decision points. However\, asking someone to mentor you and managing that relationship could be at times nerve-wracking. \nWCT is excited to offer a webinar that will help mentors and mentees achieve the most from any mentorship engagement. Fiona Gao\, a global marketing leader\, and Angela Brown\, President and CEO of Moneris\, recently participated in the WCT Protégé Project. Based on their experience\, they have released a white paper entitled “The Modern Mentor: Reimagining the Interconnectedness of Women in Business\,” which provides excellent advice for those in a mentorship or sponsorship relationship. \nDate: April 15\, 2020\nTime: 9am-10am PST\nRegister: here
URL:https://scienceinboston.com/event/webinar-the-modern-mentor-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200420T150000
DTEND;TZID=America/Vancouver:20200420T163000
DTSTAMP:20200417T210111Z
CREATED:20200417T210111Z
LAST-MODIFIED:20200417T210111Z
UID:8769-1587394800-1587400200@scienceinboston.com
SUMMARY:Responding to COVID-19: Opportunities for All Researchers to Engage
DESCRIPTION:Right now\, all eyes are on an urgent science issue and its effects on our society. While everyone has a role to play in reducing the spread of the virus\, scientists have unique opportunities to respond to the crisis in impactful ways. For example\, some scientists might volunteer their lab or data analysis skills. Regardless of discipline\, researchers may find opportunities to pivot their research agenda to address timely and relevant questions. And others might serve as voices for science to amplify evidence\, reduce the spread of misinformation\, and advocate for science-informed approaches to managing the pandemic. This online panel discussion will include researchers from different disciplines who will share ideas for scientists looking to respond in the current moment.
URL:https://scienceinboston.com/event/responding-to-covid-19-opportunities-for-all-researchers-to-engage/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200420T150000
DTEND;TZID=America/Vancouver:20200420T163000
DTSTAMP:20200417T210111Z
CREATED:20200417T210111Z
LAST-MODIFIED:20200417T210111Z
UID:27467-1587394800-1587400200@scienceinboston.com
SUMMARY:Responding to COVID-19: Opportunities for All Researchers to Engage
DESCRIPTION:Right now\, all eyes are on an urgent science issue and its effects on our society. While everyone has a role to play in reducing the spread of the virus\, scientists have unique opportunities to respond to the crisis in impactful ways. For example\, some scientists might volunteer their lab or data analysis skills. Regardless of discipline\, researchers may find opportunities to pivot their research agenda to address timely and relevant questions. And others might serve as voices for science to amplify evidence\, reduce the spread of misinformation\, and advocate for science-informed approaches to managing the pandemic. This online panel discussion will include researchers from different disciplines who will share ideas for scientists looking to respond in the current moment.
URL:https://scienceinboston.com/event/responding-to-covid-19-opportunities-for-all-researchers-to-engage-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200421T110000
DTEND;TZID=America/New_York:20200421T120000
DTSTAMP:20200417T172405Z
CREATED:20200417T172405Z
LAST-MODIFIED:20200417T172405Z
UID:8737-1587466800-1587470400@scienceinboston.com
SUMMARY:COVID-19: Community Conversations - Boston University
DESCRIPTION:Join Dean Sandro Galea online for a Boston University School of Public Health community discussion about COVID-19. Students\, faculty and staff are invited to participate. Please click the link below for Zoom details. \n\n\nSTARTS:\n11:00 am on Tuesday\, April 21\, 2020\n\nENDS:\n12:00 pm on Tuesday\, April 21\, 2020\n\nLOCATION:\nZoom Meeting Online\n\nREGISTRATION:\nhttps://www.bu.edu/sph/news-events/community-events/zoom-meetings/\n\nCONTACT NAME:\nSPH Event\n\nCONTACT EMAIL:\nsphevent@bu.edu
URL:https://scienceinboston.com/event/covid-19-community-conversations-boston-university/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200421T110000
DTEND;TZID=America/New_York:20200421T120000
DTSTAMP:20200417T172405Z
CREATED:20200417T172405Z
LAST-MODIFIED:20200417T172405Z
UID:27458-1587466800-1587470400@scienceinboston.com
SUMMARY:COVID-19: Community Conversations - Boston University
DESCRIPTION:Join Dean Sandro Galea online for a Boston University School of Public Health community discussion about COVID-19. Students\, faculty and staff are invited to participate. Please click the link below for Zoom details. \n\n\nSTARTS:\n11:00 am on Tuesday\, April 21\, 2020\n\nENDS:\n12:00 pm on Tuesday\, April 21\, 2020\n\nLOCATION:\nZoom Meeting Online\n\nREGISTRATION:\nhttps://www.bu.edu/sph/news-events/community-events/zoom-meetings/\n\nCONTACT NAME:\nSPH Event\n\nCONTACT EMAIL:\nsphevent@bu.edu
URL:https://scienceinboston.com/event/covid-19-community-conversations-boston-university-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T120000
DTEND;TZID=America/Vancouver:20200421T130000
DTSTAMP:20200415T182656Z
CREATED:20200415T182656Z
LAST-MODIFIED:20200415T182656Z
UID:8709-1587470400-1587474000@scienceinboston.com
SUMMARY:Special LINUS Report: Major Updates on Scientific Progress Amidst a Global Pandemic
DESCRIPTION:Having embarked on a longitudinal study to understand the impact of Coronavirus across life sciences\, we have identified four phases for how the pandemic will cause disruptions to the industry. Now\, with a second major data-collection time point\, and over 2\,000 respondents\, we have found major updates on what the life science community is thinking\, feeling and doing as coronavirus continues to affect our realities and shapes productivity. In this next wave of our research\, we will reveal the magnitude of the disruption to productivity\, the progress of workplace transitions\, and the developing sentiment felt across the industry.
URL:https://scienceinboston.com/event/special-linus-report-major-updates-on-scientific-progress-amidst-a-global-pandemic/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T120000
DTEND;TZID=America/Vancouver:20200421T130000
DTSTAMP:20200415T182656Z
CREATED:20200415T182656Z
LAST-MODIFIED:20200415T182656Z
UID:27453-1587470400-1587474000@scienceinboston.com
SUMMARY:Special LINUS Report: Major Updates on Scientific Progress Amidst a Global Pandemic
DESCRIPTION:Having embarked on a longitudinal study to understand the impact of Coronavirus across life sciences\, we have identified four phases for how the pandemic will cause disruptions to the industry. Now\, with a second major data-collection time point\, and over 2\,000 respondents\, we have found major updates on what the life science community is thinking\, feeling and doing as coronavirus continues to affect our realities and shapes productivity. In this next wave of our research\, we will reveal the magnitude of the disruption to productivity\, the progress of workplace transitions\, and the developing sentiment felt across the industry.
URL:https://scienceinboston.com/event/special-linus-report-major-updates-on-scientific-progress-amidst-a-global-pandemic-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200421T130000
DTEND;TZID=America/New_York:20200421T140000
DTSTAMP:20200330T175726Z
CREATED:20200330T175726Z
LAST-MODIFIED:20200330T175726Z
UID:8572-1587474000-1587477600@scienceinboston.com
SUMMARY:Vascular Specification and Development
DESCRIPTION:An online mini-symposium featuring four presentations: Renal stromal netrin-1 signaling drives kidney arterial development (Xiaowu Gu\, UT Southwestern) Inhibition of Notch signaling in pericytes leads to AVM-like lesions (Taliha Nadeem\, University of Illinois\, Chicago) Dach1 Promotes Coronary Artery Endothelial Cell Specification (Brian Raftrey\, Stanford University) Pro-angiogenic properties of Purified Exosome Product (PEP) (Ao Shi\, Mayo Clinic) The session will be moderated by Kayla Bayless\, Texas A&M University
URL:https://scienceinboston.com/event/vascular-specification-and-development/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200421T130000
DTEND;TZID=America/New_York:20200421T140000
DTSTAMP:20200330T175726Z
CREATED:20200330T175726Z
LAST-MODIFIED:20200330T175726Z
UID:27445-1587474000-1587477600@scienceinboston.com
SUMMARY:Vascular Specification and Development
DESCRIPTION:An online mini-symposium featuring four presentations: Renal stromal netrin-1 signaling drives kidney arterial development (Xiaowu Gu\, UT Southwestern) Inhibition of Notch signaling in pericytes leads to AVM-like lesions (Taliha Nadeem\, University of Illinois\, Chicago) Dach1 Promotes Coronary Artery Endothelial Cell Specification (Brian Raftrey\, Stanford University) Pro-angiogenic properties of Purified Exosome Product (PEP) (Ao Shi\, Mayo Clinic) The session will be moderated by Kayla Bayless\, Texas A&M University
URL:https://scienceinboston.com/event/vascular-specification-and-development-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T133000
DTEND;TZID=America/Vancouver:20200421T143000
DTSTAMP:20200420T211951Z
CREATED:20200420T211951Z
LAST-MODIFIED:20200420T211951Z
UID:8794-1587475800-1587479400@scienceinboston.com
SUMMARY:Innovation and Biotech in the Time of COVID-19: View from the Frontlines
DESCRIPTION:This three-part webinar series will feature biotech industry leaders\, experts\, and entrepreneurs discussing COVID-19 and its impact on innovation. \nIn our third panel\, hear from front-line workers. They’ll detail what they’re facing and how the biotech community can help. \nSpeakers include: \nRichard Malley\, Senior Physician in Medicine\, Division of Infectious Diseases\, Boston Children’s Hospital & Scientific Founder of Affinivax \nRick Malley\, M.D.\, began his education at the Ecole Active Bilingue in Paris\, France\, getting his Baccalaureate in 1982. He received his B.A. from Yale University\, his M.D. from Tufts University in 1990\, and pediatric infectious diseases and emergency medicine training at Boston Children’s Hospital. In 1997\, a chance meeting with Dr. Porter Anderson (one of the co-inventors of the Haemophilus influenzae type b conjugate vaccine) led to his interest in the development of a species-specific pneumococcal vaccine for use in developing countries and vaccinology in general. Under Dr. Anderson’s mentorship\, he shifted his research to the development of novel vaccines against pneumococcus and other pathogens\, leading to numerous scientific publications describing various aspects of pneumococcal pathogenesis and prevention\, such as acquired and innate immunity\, correlates of protection\, and mechanisms of protection from nasopharyngeal colonization. \nDr. Malley is the Kenneth McIntosh Chair in Pediatric Infectious Diseases at Boston Children’s Hospital and Professor of Pediatrics at Harvard Medical School. Dr. Malley regularly attends on the Pediatric Infectious Diseases service at Boston Children’s Hospital\, providing consultation on inpatients. He is also the Director of the Travel and Geographic Medicine Clinic\, providing advice\, vaccines and medications to both adult and pediatric travelers. \nDr. Malley runs a research laboratory with past and present funding from the Meningitis Research Foundation\, NIH\, PATH and the Bill and Melinda Gates Foundation (BMGF)\, focusing on vaccine development for pneumococcus\, Staphylococcus aureus\, Salmonella typhi and paratyphi\, and Mycobacterium tuberculosis and more recently SARS-CoV-2. In collaboration with PATH and the BMGF\, Dr. Malley led an international effort for the development of a a pneumococcal vaccine for developing countries. In 2014\, Dr. Malley and collaborators started Affinivax\, a biotechnology company seed-funded by BMGF and based on a novel technology called MAPS (Multiple Antigen Presenting System) to develop vaccines for developing countries. Streptococcus pneumoniae is the lead target being developed at Affinivax. A pneumococcal MAPS vaccine is currently in Phase 2 clinical testing in older adults. \nJoshua Resnick\, Physician at the Department of Emergency Medicine at Massachusetts General Hospital and Managing Director at RA Capital Management \nJosh Resnick is a Managing Director at RA Capital Management. Josh’s primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs\, medical devices\, diagnostics\, and research tools. Josh holds a BA in Chemistry from Williams College\, an MD from the University of Pennsylvania School of Medicine\, and an MBA from the Wharton School of Business. He has more than 15 years of experience in investing\, company formation\, and company leadership across all stages of drug development\, from discovery through commercialization. Josh was previously co-lead of SV Health Investors’ US Biotech practice where he was responsible for SV’s US venture creation activities\, including its incubator\, Brahma Discovery. Before SV\, Josh was President and Managing Partner at MRL Ventures Fund\, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Prior to MRL Ventures\, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners\, focusing on company formation and seed and Series A investing. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital \nHannu Rajaniemi\, Co-Founder and CEO of HelixNano \nHannu Rajaniemi is a co-founder and CEO of HelixNano\, a venture- and Y Combinator backed biotech startup. HelixNano’s ultimate mission is to build technologies that unlock a future where freedom from cancer is a fundamental human right. But right now\, the fight against a global pandemic needs all scientific hands on deck. In response to this existential challenge\, the team is applying its expertise to deploy a novel vaccination approach against COVID-19. \nHannu was born in Finland. At the age of eight he approached the European Space Agency with a fusion-powered spaceship design\, which was received with a polite “thank you” note. Hannu studied mathematics and theoretical physics at University of Oulu and Cambridge and holds a PhD in string theory from the University of Edinburgh. He co-founded a mathematics consultancy whose clients included UK Ministry of Defence and the European Space Agency. \nHannu is the author of four novels including The Quantum Thief (winner of 2012 Tähtivaeltaja Award for the best science fiction novel published in Finland and translated into more than 20 languages). His most recent book is Summerland (June 2018)\, an alternate history spy thriller in a world where the afterlife is real. His short fiction has been featured in Nature\, Slate\, MIT Technology Review and The New York Times. \nHannu lives in the San Francisco Bay Area with his wife\, neuroscientist Zuzana Krejciova-Rajaniemi\, and their vizsla puppy Neo. \nWe hope to help you see a few steps further into the future and enjoy some realistic optimism for the next few months! \nOur webinar will be hosted on YouTube Live. Registrants will receive the link in an email shortly before broadcast. \nContact emulcahy@labcentral.org with questions.
URL:https://scienceinboston.com/event/innovation-and-biotech-in-the-time-of-covid-19-view-from-the-frontlines/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinboston.com/wp-content/uploads/sites/6/2020/04/Innovation-and-Biotech-in-the-Time-of-COVID-19.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T133000
DTEND;TZID=America/Vancouver:20200421T143000
DTSTAMP:20200420T211951Z
CREATED:20200420T211951Z
LAST-MODIFIED:20200420T211951Z
UID:27469-1587475800-1587479400@scienceinboston.com
SUMMARY:Innovation and Biotech in the Time of COVID-19: View from the Frontlines
DESCRIPTION:This three-part webinar series will feature biotech industry leaders\, experts\, and entrepreneurs discussing COVID-19 and its impact on innovation. \nIn our third panel\, hear from front-line workers. They’ll detail what they’re facing and how the biotech community can help. \nSpeakers include: \nRichard Malley\, Senior Physician in Medicine\, Division of Infectious Diseases\, Boston Children’s Hospital & Scientific Founder of Affinivax \nRick Malley\, M.D.\, began his education at the Ecole Active Bilingue in Paris\, France\, getting his Baccalaureate in 1982. He received his B.A. from Yale University\, his M.D. from Tufts University in 1990\, and pediatric infectious diseases and emergency medicine training at Boston Children’s Hospital. In 1997\, a chance meeting with Dr. Porter Anderson (one of the co-inventors of the Haemophilus influenzae type b conjugate vaccine) led to his interest in the development of a species-specific pneumococcal vaccine for use in developing countries and vaccinology in general. Under Dr. Anderson’s mentorship\, he shifted his research to the development of novel vaccines against pneumococcus and other pathogens\, leading to numerous scientific publications describing various aspects of pneumococcal pathogenesis and prevention\, such as acquired and innate immunity\, correlates of protection\, and mechanisms of protection from nasopharyngeal colonization. \nDr. Malley is the Kenneth McIntosh Chair in Pediatric Infectious Diseases at Boston Children’s Hospital and Professor of Pediatrics at Harvard Medical School. Dr. Malley regularly attends on the Pediatric Infectious Diseases service at Boston Children’s Hospital\, providing consultation on inpatients. He is also the Director of the Travel and Geographic Medicine Clinic\, providing advice\, vaccines and medications to both adult and pediatric travelers. \nDr. Malley runs a research laboratory with past and present funding from the Meningitis Research Foundation\, NIH\, PATH and the Bill and Melinda Gates Foundation (BMGF)\, focusing on vaccine development for pneumococcus\, Staphylococcus aureus\, Salmonella typhi and paratyphi\, and Mycobacterium tuberculosis and more recently SARS-CoV-2. In collaboration with PATH and the BMGF\, Dr. Malley led an international effort for the development of a a pneumococcal vaccine for developing countries. In 2014\, Dr. Malley and collaborators started Affinivax\, a biotechnology company seed-funded by BMGF and based on a novel technology called MAPS (Multiple Antigen Presenting System) to develop vaccines for developing countries. Streptococcus pneumoniae is the lead target being developed at Affinivax. A pneumococcal MAPS vaccine is currently in Phase 2 clinical testing in older adults. \nJoshua Resnick\, Physician at the Department of Emergency Medicine at Massachusetts General Hospital and Managing Director at RA Capital Management \nJosh Resnick is a Managing Director at RA Capital Management. Josh’s primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs\, medical devices\, diagnostics\, and research tools. Josh holds a BA in Chemistry from Williams College\, an MD from the University of Pennsylvania School of Medicine\, and an MBA from the Wharton School of Business. He has more than 15 years of experience in investing\, company formation\, and company leadership across all stages of drug development\, from discovery through commercialization. Josh was previously co-lead of SV Health Investors’ US Biotech practice where he was responsible for SV’s US venture creation activities\, including its incubator\, Brahma Discovery. Before SV\, Josh was President and Managing Partner at MRL Ventures Fund\, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Prior to MRL Ventures\, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners\, focusing on company formation and seed and Series A investing. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital \nHannu Rajaniemi\, Co-Founder and CEO of HelixNano \nHannu Rajaniemi is a co-founder and CEO of HelixNano\, a venture- and Y Combinator backed biotech startup. HelixNano’s ultimate mission is to build technologies that unlock a future where freedom from cancer is a fundamental human right. But right now\, the fight against a global pandemic needs all scientific hands on deck. In response to this existential challenge\, the team is applying its expertise to deploy a novel vaccination approach against COVID-19. \nHannu was born in Finland. At the age of eight he approached the European Space Agency with a fusion-powered spaceship design\, which was received with a polite “thank you” note. Hannu studied mathematics and theoretical physics at University of Oulu and Cambridge and holds a PhD in string theory from the University of Edinburgh. He co-founded a mathematics consultancy whose clients included UK Ministry of Defence and the European Space Agency. \nHannu is the author of four novels including The Quantum Thief (winner of 2012 Tähtivaeltaja Award for the best science fiction novel published in Finland and translated into more than 20 languages). His most recent book is Summerland (June 2018)\, an alternate history spy thriller in a world where the afterlife is real. His short fiction has been featured in Nature\, Slate\, MIT Technology Review and The New York Times. \nHannu lives in the San Francisco Bay Area with his wife\, neuroscientist Zuzana Krejciova-Rajaniemi\, and their vizsla puppy Neo. \nWe hope to help you see a few steps further into the future and enjoy some realistic optimism for the next few months! \nOur webinar will be hosted on YouTube Live. Registrants will receive the link in an email shortly before broadcast. \nContact emulcahy@labcentral.org with questions.
URL:https://scienceinboston.com/event/innovation-and-biotech-in-the-time-of-covid-19-view-from-the-frontlines-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinboston.com/wp-content/uploads/sites/6/2020/04/Innovation-and-Biotech-in-the-Time-of-COVID-19.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T190000
DTEND;TZID=America/Vancouver:20200421T203000
DTSTAMP:20200415T224108Z
CREATED:20200415T224108Z
LAST-MODIFIED:20200415T224108Z
UID:8734-1587495600-1587501000@scienceinboston.com
SUMMARY:Planning For The Regulatory Environment Of Your Life Sciences Startup
DESCRIPTION:Start-ups are hard work. Launching a start-up is difficult\, time consuming and fraught with challenges and risks. Operating an emerging company to achieve financial success is also difficult and risky\, with untold obstacles to success in product R&D\, financing\, operations\, business development…and the list goes on.  \nIf the day to day challenges of entrepreneurship seem daunting\, life sciences entrepreneurs often have another (not so small) detail to contend with. Regulatory approval\, through government agencies like the U.S. FDA and the EU’s EMA\, may be required before a product reaches the market – requiring rigorous (and expensive) clinical trials and highly regulated manufacturing processes\, among other details.  \nENET is here to help; we’re all about offering practical insights\, from experienced industry veterans\, to help entrepreneurs to succeed. Tonight’s panel will offer insights on how to prepare for meeting rigorous regulatory requirements and even when to get started thinking about regulatory affairs. \nAgenda: \n7:00 7:15 PM – ENET Chairperson’s announcements \n7:15  7:30 PM – eMinute – Up to 3 Startup companies’ presentations \n7:30  8:15 PM – 3 expert speakers on the night’s topic \nA question and answer session follow the presentations \nRegister here: https://bit.ly/ENET2916w
URL:https://scienceinboston.com/event/planning-for-the-regulatory-environment-of-your-life-sciences-startup/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T190000
DTEND;TZID=America/Vancouver:20200421T203000
DTSTAMP:20200415T224108Z
CREATED:20200415T224108Z
LAST-MODIFIED:20200415T224108Z
UID:27457-1587495600-1587501000@scienceinboston.com
SUMMARY:Planning For The Regulatory Environment Of Your Life Sciences Startup
DESCRIPTION:Start-ups are hard work. Launching a start-up is difficult\, time consuming and fraught with challenges and risks. Operating an emerging company to achieve financial success is also difficult and risky\, with untold obstacles to success in product R&D\, financing\, operations\, business development…and the list goes on.  \nIf the day to day challenges of entrepreneurship seem daunting\, life sciences entrepreneurs often have another (not so small) detail to contend with. Regulatory approval\, through government agencies like the U.S. FDA and the EU’s EMA\, may be required before a product reaches the market – requiring rigorous (and expensive) clinical trials and highly regulated manufacturing processes\, among other details.  \nENET is here to help; we’re all about offering practical insights\, from experienced industry veterans\, to help entrepreneurs to succeed. Tonight’s panel will offer insights on how to prepare for meeting rigorous regulatory requirements and even when to get started thinking about regulatory affairs. \nAgenda: \n7:00 7:15 PM – ENET Chairperson’s announcements \n7:15  7:30 PM – eMinute – Up to 3 Startup companies’ presentations \n7:30  8:15 PM – 3 expert speakers on the night’s topic \nA question and answer session follow the presentations \nRegister here: https://bit.ly/ENET2916w
URL:https://scienceinboston.com/event/planning-for-the-regulatory-environment-of-your-life-sciences-startup-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T080000
DTEND;TZID=America/Vancouver:20200425T170000
DTSTAMP:20200413T220903Z
CREATED:20200413T220903Z
LAST-MODIFIED:20200413T220903Z
UID:8684-1587542400-1587834000@scienceinboston.com
SUMMARY:The Allied Genetics Conference (TAGC) Online
DESCRIPTION:TAGC is a unique conference organized by the Genetics Society of America that fosters collaboration by alternating community-specific sessions with cross-community thematic sessions. After the in-person version of the meeting was canceled\, we recreated TAGC Online as a virtual meeting that allows you to share your research and stay connected without leaving your home. \nJoin us online April 22–25\, 2020. There is no cost to attend\, but you must register in advance! \nAt TAGC Online you can join colleagues from the C. elegans\,  Drosophila\, mammalian\, Xenopus\, yeast\, zebrafish\, and population\, evolutionary\, and quantitative genetics (PEQG) research communities—along with other researchers studying humans\, plants\, and agricultural species. In addition to the Community Sessions\, Thematic Sessions bring the communities together around unifying themes. \nOn April 22–25\, both Community and Thematic Sessions will be presented live online. TAGC 2020 Online will also include posters and inspiring Keynote Speakers\, followed by a program of poster discussion sessions and two-hour workshops in the weeks after the main event. TAGC 2020 is organized by dedicated members of the GSA community. We hope you’ll join us for this exciting experiment!
URL:https://scienceinboston.com/event/the-allied-genetics-conference-tagc-online/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T080000
DTEND;TZID=America/Vancouver:20200425T170000
DTSTAMP:20200413T220903Z
CREATED:20200413T220903Z
LAST-MODIFIED:20200413T220903Z
UID:27449-1587542400-1587834000@scienceinboston.com
SUMMARY:The Allied Genetics Conference (TAGC) Online
DESCRIPTION:TAGC is a unique conference organized by the Genetics Society of America that fosters collaboration by alternating community-specific sessions with cross-community thematic sessions. After the in-person version of the meeting was canceled\, we recreated TAGC Online as a virtual meeting that allows you to share your research and stay connected without leaving your home. \nJoin us online April 22–25\, 2020. There is no cost to attend\, but you must register in advance! \nAt TAGC Online you can join colleagues from the C. elegans\,  Drosophila\, mammalian\, Xenopus\, yeast\, zebrafish\, and population\, evolutionary\, and quantitative genetics (PEQG) research communities—along with other researchers studying humans\, plants\, and agricultural species. In addition to the Community Sessions\, Thematic Sessions bring the communities together around unifying themes. \nOn April 22–25\, both Community and Thematic Sessions will be presented live online. TAGC 2020 Online will also include posters and inspiring Keynote Speakers\, followed by a program of poster discussion sessions and two-hour workshops in the weeks after the main event. TAGC 2020 is organized by dedicated members of the GSA community. We hope you’ll join us for this exciting experiment!
URL:https://scienceinboston.com/event/the-allied-genetics-conference-tagc-online-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200422T100000
DTEND;TZID=America/New_York:20200422T103000
DTSTAMP:20200415T223409Z
CREATED:20200415T223333Z
LAST-MODIFIED:20200415T223409Z
UID:8728-1587549600-1587551400@scienceinboston.com
SUMMARY:Online Short-Seminar: Let’s Make Research Data FAIR
DESCRIPTION:Current challenges of data-intensive science relate to how we doscover\, access\, integrate and analyze research data. To overcome these challenges\, the FAIR Data Principles have been created as guidance to make data Findable\, Accessible\, Interoperable\, and Reusable. \nThis virtual session will review what you need to know about FAIR data and how standard data management practices make your data FAIR. \nLearning Objectives: \n\nUnderstand FAIR Principles for research data\nUnderstand how data management practices enable FAIR data\nFind out who to contact for assistance\n\nInstructor: Julie Goldman\, Research Data Services\, Countway Library\, julie_goldman@hms.harvard.edu
URL:https://scienceinboston.com/event/online-short-seminar-lets-make-research-data-fair/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinboston.com/wp-content/uploads/sites/6/2020/04/FAIR_Data.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200422T100000
DTEND;TZID=America/New_York:20200422T103000
DTSTAMP:20200415T223333Z
CREATED:20200415T223333Z
LAST-MODIFIED:20200415T223333Z
UID:27455-1587549600-1587551400@scienceinboston.com
SUMMARY:Online Short-Seminar: Let’s Make Research Data FAIR
DESCRIPTION:Current challenges of data-intensive science relate to how we doscover\, access\, integrate and analyze research data. To overcome these challenges\, the FAIR Data Principles have been created as guidance to make data Findable\, Accessible\, Interoperable\, and Reusable. \nThis virtual session will review what you need to know about FAIR data and how standard data management practices make your data FAIR. \nLearning Objectives: \n\nUnderstand FAIR Principles for research data\nUnderstand how data management practices enable FAIR data\nFind out who to contact for assistance\n\nInstructor: Julie Goldman\, Research Data Services\, Countway Library\, julie_goldman@hms.harvard.edu
URL:https://scienceinboston.com/event/online-short-seminar-lets-make-research-data-fair-2/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinboston.com/wp-content/uploads/sites/6/2020/04/FAIR_Data.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200422T120000
DTEND;TZID=America/New_York:20200422T130000
DTSTAMP:20200406T145054Z
CREATED:20200406T145054Z
LAST-MODIFIED:20200406T145054Z
UID:8603-1587556800-1587560400@scienceinboston.com
SUMMARY:Every Cell Has Its Place: In Situ Sequencing of Tissue Samples at Single-Cell Resolution
DESCRIPTION:Single-cell RNA sequencing (scRNA-seq) has revolutionized the understanding of tissue complexity by dissecting transcriptomic heterogeneity and revealing previously unknown cell types and states. However\, scRNA-seq does not allow the visualization of spatial organization of single cells within the tissue. In order to overcome this limitation\, spatial gene expression profiling technologies have emerged that aim to localize molecularly defined cell types within the morphological context. In situ sequencing (ISS) can rapidly analyze and visualize the expression of hundreds of genes within morphologically intact tissue samples at single-cell resolution. ISS helps researchers to understand complex biological and pathological mechanisms and to localize and validate new drug targets. \nIn this webinar\, we will outline the benefits of ISS and showcase how it can complement spatial transcriptomics technology in the task of unraveling the role of amyloid-ß plaques in the neurogenerative process of Alzheimer’s disease. \nDuring this webinar\, the speakers will: \n\nIntroduce ISS technology and how it enables simultaneous spatial analysis of hundreds of genes in tissue samples at single-cell resolution\nShow how ISS has helped shed light on the role of amyloid-ß plaques in Alzheimer’s disease\nDiscuss applications and performance of ISS in other research areas\nAnswer your questions during the live broadcast.\n\nThis webinar will last for approximately 60 minutes. \n\nSpeaker bios\n\n\n\nBart De Strooper\, M.D.\, Ph.D.\nVIB-KU Leuven Center for Brain & Disease Research\nLeuven\, Belgium \n\nDr. DeStrooper graduated from KU Leuven\, first as a Doctor of Medicine (1985) and then as a Master’s in biomedical sciences (1987). After obtaining his doctorate in 1991 and completing postgraduate studies in 1999 under the supervision of Fred van Leuven and Carlos Dotti (European Molecular Biology Laboratory\, Germany)\, in which he studied presenilins in Alzheimer’s disease (AD)\, he started an independent research laboratory at KU Leuven and VIB. His multidisciplinary\, international research group has grown to 30 people\, and his lab studies both Alzheimer’s and Parkinson’s disease. His research spans biochemistry and enzymology of γ-secretase; microRNA biology and expression deregulation; genetic and transcriptomic analysis of AD patients’ brains; generation of novel humanized mouse models for AD; mitochondrial biology; and the development of nanobodies against therapeutically relevant targets. Currently\, Dr. DeStrooper is pioneering the application of single-cell genomics-transcriptomics and spatial transcriptomics to the study of Alzheimer’s disease. Since 2017 he has been founding director of the UK Dementia Research Institute. \n\n\n\n\n\n\nMalte Kuhnemund\, Ph.D.\nCARTANA\nSolna\, Sweden \n\nDr. Kühnemund obtained a Master’s in biochemistry and cell biology at the Braunschweig University of Technology (Germany) and Lund University (Sweden). He then joined the Nilsson and Landegren labs in Sweden\, where he obtained his Ph.D. in molecular medicine from Uppsala University and the Science for Life Laboratory (Sweden). His work on single-molecule analysis and sequencing technologies is now part of the technology portfolio of CARTANA\, an in-situ-sequencing (ISS) company spun out from the Nilsson lab. Dr. Kühnemund is a cofounder of CARTANA and head of R&D at the company\, which makes ISS technology available to the global research community. \n\n\n\n\n\n\nJackie Oberst\, Ph.D.\nScience/AAAS\nWashington\, D.C. \n\nDr. Oberst did her undergraduate training at the University of Maryland\, College Park\, and her Ph.D. in Tumor Biology at Georgetown University\, Washington D.C. She combined her interests in science and writing by pursuing an M.A. in Journalism from the Philip Merrill College of Journalism at the University of Maryland\, College Park. Dr. Oberst joined Science/AAAS in 2016 as the Assistant Editor for Custom Publishing. Before then she worked at Nature magazine\, the Howard Hughes Medical Institute\, The Endocrine Society\, and the National Institutes of Mental Health.
URL:https://scienceinboston.com/event/every-cell-has-its-place-in-situ-sequencing-of-tissue-samples-at-single-cell-resolution/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200422T120000
DTEND;TZID=America/New_York:20200422T130000
DTSTAMP:20200406T145054Z
CREATED:20200406T145054Z
LAST-MODIFIED:20200406T145054Z
UID:27446-1587556800-1587560400@scienceinboston.com
SUMMARY:Every Cell Has Its Place: In Situ Sequencing of Tissue Samples at Single-Cell Resolution
DESCRIPTION:Single-cell RNA sequencing (scRNA-seq) has revolutionized the understanding of tissue complexity by dissecting transcriptomic heterogeneity and revealing previously unknown cell types and states. However\, scRNA-seq does not allow the visualization of spatial organization of single cells within the tissue. In order to overcome this limitation\, spatial gene expression profiling technologies have emerged that aim to localize molecularly defined cell types within the morphological context. In situ sequencing (ISS) can rapidly analyze and visualize the expression of hundreds of genes within morphologically intact tissue samples at single-cell resolution. ISS helps researchers to understand complex biological and pathological mechanisms and to localize and validate new drug targets. \nIn this webinar\, we will outline the benefits of ISS and showcase how it can complement spatial transcriptomics technology in the task of unraveling the role of amyloid-ß plaques in the neurogenerative process of Alzheimer’s disease. \nDuring this webinar\, the speakers will: \n\nIntroduce ISS technology and how it enables simultaneous spatial analysis of hundreds of genes in tissue samples at single-cell resolution\nShow how ISS has helped shed light on the role of amyloid-ß plaques in Alzheimer’s disease\nDiscuss applications and performance of ISS in other research areas\nAnswer your questions during the live broadcast.\n\nThis webinar will last for approximately 60 minutes. \n\nSpeaker bios\n\n\n\nBart De Strooper\, M.D.\, Ph.D.\nVIB-KU Leuven Center for Brain & Disease Research\nLeuven\, Belgium \n\nDr. DeStrooper graduated from KU Leuven\, first as a Doctor of Medicine (1985) and then as a Master’s in biomedical sciences (1987). After obtaining his doctorate in 1991 and completing postgraduate studies in 1999 under the supervision of Fred van Leuven and Carlos Dotti (European Molecular Biology Laboratory\, Germany)\, in which he studied presenilins in Alzheimer’s disease (AD)\, he started an independent research laboratory at KU Leuven and VIB. His multidisciplinary\, international research group has grown to 30 people\, and his lab studies both Alzheimer’s and Parkinson’s disease. His research spans biochemistry and enzymology of γ-secretase; microRNA biology and expression deregulation; genetic and transcriptomic analysis of AD patients’ brains; generation of novel humanized mouse models for AD; mitochondrial biology; and the development of nanobodies against therapeutically relevant targets. Currently\, Dr. DeStrooper is pioneering the application of single-cell genomics-transcriptomics and spatial transcriptomics to the study of Alzheimer’s disease. Since 2017 he has been founding director of the UK Dementia Research Institute. \n\n\n\n\n\n\nMalte Kuhnemund\, Ph.D.\nCARTANA\nSolna\, Sweden \n\nDr. Kühnemund obtained a Master’s in biochemistry and cell biology at the Braunschweig University of Technology (Germany) and Lund University (Sweden). He then joined the Nilsson and Landegren labs in Sweden\, where he obtained his Ph.D. in molecular medicine from Uppsala University and the Science for Life Laboratory (Sweden). His work on single-molecule analysis and sequencing technologies is now part of the technology portfolio of CARTANA\, an in-situ-sequencing (ISS) company spun out from the Nilsson lab. Dr. Kühnemund is a cofounder of CARTANA and head of R&D at the company\, which makes ISS technology available to the global research community. \n\n\n\n\n\n\nJackie Oberst\, Ph.D.\nScience/AAAS\nWashington\, D.C. \n\nDr. Oberst did her undergraduate training at the University of Maryland\, College Park\, and her Ph.D. in Tumor Biology at Georgetown University\, Washington D.C. She combined her interests in science and writing by pursuing an M.A. in Journalism from the Philip Merrill College of Journalism at the University of Maryland\, College Park. Dr. Oberst joined Science/AAAS in 2016 as the Assistant Editor for Custom Publishing. Before then she worked at Nature magazine\, the Howard Hughes Medical Institute\, The Endocrine Society\, and the National Institutes of Mental Health.
URL:https://scienceinboston.com/event/every-cell-has-its-place-in-situ-sequencing-of-tissue-samples-at-single-cell-resolution-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T120000
DTEND;TZID=America/Vancouver:20200422T130000
DTSTAMP:20200415T223127Z
CREATED:20200415T223127Z
LAST-MODIFIED:20200415T223127Z
UID:8726-1587556800-1587560400@scienceinboston.com
SUMMARY:Strategic Approaches To Developing and Commercializing Companion Diagnostics
DESCRIPTION:The COVID-19 pandemic has proven the importance of diagnostic tests in overcoming healthcare crises and saving lives; but it has required rapid scale up and deployment of point of care and lab based tests hopefully with lessons learned for the future. Join us to learn more about the journey of developing a companion diagnostic from discovery through commercialization. \nPrecision medicine is an emerging method that factors in an individual’s molecular profile\, environment\, and lifestyle in order to prevent\, diagnose\, and treat diseases more effectively. It’s about considering individual differences in the course of prevention\, diagnosis\, and treatment. \nPatients can be classified into subgroups based on how susceptible they are to certain diseases\, how those diseases will develop\, or how they’ll respond to particular treatments. This information can then be used to predict what the most effective course of action will be. Companion Diagnostics are tools employed to identify those patients who are most likely to benefit from a particular therapeutic product\, highlight those at increased risk for serious side effects\, and monitor treatment response. \nBut what about those tasked with bringing precision medicine tests and treatments to the market? What are they doing\, what challenges do they face\, and how are they working with stakeholders within the wider healthcare ecosystem? We’ll follow the journey of developing a companion diagnostic from discovery through commercialization and answer those questions in this informative forum. Please come prepared with your questions. \nSponsored by the Medtech/Digital Health working group. \nNOTE: As MassBio transitions to virtual events\, we are striving to make them as inclusive as possible given the challenges and restrictions inherent in virtual events. Thank you for your understanding.
URL:https://scienceinboston.com/event/strategic-approaches-to-developing-and-commercializing-companion-diagnostics/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T120000
DTEND;TZID=America/Vancouver:20200422T130000
DTSTAMP:20200415T223127Z
CREATED:20200415T223127Z
LAST-MODIFIED:20200415T223127Z
UID:27454-1587556800-1587560400@scienceinboston.com
SUMMARY:Strategic Approaches To Developing and Commercializing Companion Diagnostics
DESCRIPTION:The COVID-19 pandemic has proven the importance of diagnostic tests in overcoming healthcare crises and saving lives; but it has required rapid scale up and deployment of point of care and lab based tests hopefully with lessons learned for the future. Join us to learn more about the journey of developing a companion diagnostic from discovery through commercialization. \nPrecision medicine is an emerging method that factors in an individual’s molecular profile\, environment\, and lifestyle in order to prevent\, diagnose\, and treat diseases more effectively. It’s about considering individual differences in the course of prevention\, diagnosis\, and treatment. \nPatients can be classified into subgroups based on how susceptible they are to certain diseases\, how those diseases will develop\, or how they’ll respond to particular treatments. This information can then be used to predict what the most effective course of action will be. Companion Diagnostics are tools employed to identify those patients who are most likely to benefit from a particular therapeutic product\, highlight those at increased risk for serious side effects\, and monitor treatment response. \nBut what about those tasked with bringing precision medicine tests and treatments to the market? What are they doing\, what challenges do they face\, and how are they working with stakeholders within the wider healthcare ecosystem? We’ll follow the journey of developing a companion diagnostic from discovery through commercialization and answer those questions in this informative forum. Please come prepared with your questions. \nSponsored by the Medtech/Digital Health working group. \nNOTE: As MassBio transitions to virtual events\, we are striving to make them as inclusive as possible given the challenges and restrictions inherent in virtual events. Thank you for your understanding.
URL:https://scienceinboston.com/event/strategic-approaches-to-developing-and-commercializing-companion-diagnostics-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T130000
DTEND;TZID=America/Vancouver:20200422T140000
DTSTAMP:20200415T182259Z
CREATED:20200415T182259Z
LAST-MODIFIED:20200415T182259Z
UID:8704-1587560400-1587564000@scienceinboston.com
SUMMARY:STAT Digital Event: Antiviral Treatments. What Are the Odds?
DESCRIPTION:The pandemic caused by the novel coronavirus has shut down countries around the world. One of society’s biggest hopes is that treatments or even vaccines can be developed. \nJoin STAT for a three-part digital event series covering the race for new medicines that will impact Covid-19. The audience will be joined by executives from companies leading the way in developing treatments\, who will come prepared to answer tough questions. They’ll discuss current findings\, clinical trials\, and efforts to expedite approvals as we face this global pandemic. \nThis series will take place on Zoom\, an interactive platform where attendees will be able to not only see the discussions live\, but also participate by asking questions during the event. Access to the event is free. Access to the Zoom platform is limited to the first 1\,000 attendees; any additional attendees will be able to watch the conversation in real-time via a live stream on STAT’s website. \nPart 2: Antiviral treatments. What are the odds? April 22\, 2020 at 1PM EST \n\nSponsor Introduction: Richard Moscicki\, M.D.\, chief medical officer and executive vice president of Science and Regulatory Advocacy\, PhRMA\nDiana Brainard\, senior vice president\, HIV and Emerging Viral Infections at Gilead Sciences\, Inc.\nMatt Herper\, senior writer\, medicine\, and editorial director of events\, STAT
URL:https://scienceinboston.com/event/stat-digital-event-antiviral-treatments-what-are-the-odds/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinboston.com/wp-content/uploads/sites/6/2020/04/STAT-Digital-Event-Series-Combating-Covid-19.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T130000
DTEND;TZID=America/Vancouver:20200422T140000
DTSTAMP:20200415T182259Z
CREATED:20200415T182259Z
LAST-MODIFIED:20200415T182259Z
UID:27452-1587560400-1587564000@scienceinboston.com
SUMMARY:STAT Digital Event: Antiviral Treatments. What Are the Odds?
DESCRIPTION:The pandemic caused by the novel coronavirus has shut down countries around the world. One of society’s biggest hopes is that treatments or even vaccines can be developed. \nJoin STAT for a three-part digital event series covering the race for new medicines that will impact Covid-19. The audience will be joined by executives from companies leading the way in developing treatments\, who will come prepared to answer tough questions. They’ll discuss current findings\, clinical trials\, and efforts to expedite approvals as we face this global pandemic. \nThis series will take place on Zoom\, an interactive platform where attendees will be able to not only see the discussions live\, but also participate by asking questions during the event. Access to the event is free. Access to the Zoom platform is limited to the first 1\,000 attendees; any additional attendees will be able to watch the conversation in real-time via a live stream on STAT’s website. \nPart 2: Antiviral treatments. What are the odds? April 22\, 2020 at 1PM EST \n\nSponsor Introduction: Richard Moscicki\, M.D.\, chief medical officer and executive vice president of Science and Regulatory Advocacy\, PhRMA\nDiana Brainard\, senior vice president\, HIV and Emerging Viral Infections at Gilead Sciences\, Inc.\nMatt Herper\, senior writer\, medicine\, and editorial director of events\, STAT
URL:https://scienceinboston.com/event/stat-digital-event-antiviral-treatments-what-are-the-odds-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinboston.com/wp-content/uploads/sites/6/2020/04/STAT-Digital-Event-Series-Combating-Covid-19.jpeg
END:VEVENT
END:VCALENDAR